Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Biogen vs. Axsome Therapeutics


If you've seen one biotech, you've seen... one biotech. They're all different, with unique opportunities and challenges. And beyond their core differences, their situations vary widely depending on what stage of their business lives they are in. 

Biogen (NASDAQ: BIIB), for example, is well established. It has made billions of dollars through the years from its multiple sclerosis (MS) franchise and has now expanded into new therapeutic categories. Axsome Therapeutics (NASDAQ: AXSM), on the other hand, is young enough that it doesn't have any approved products on the market yet, but its pipeline includes several highly promising candidates.

Which of these two biotech stocks is the better pick for long-term investors? Here's how big Biogen stacks up against up-and-coming Axsome.

Continue reading


Source Fool.com

Like: 0
Share

Comments